Metamizole is a pyrazolone nonsteroidal anti-inflammatory drug (nSAiD) with analgesic and antipyretic activity. its chemical name is sodium n-(2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)-n-methylaminomethanesulphonate; mol. w. 334.38; molecular formula: c 13 h 16 n 3 nao 4 S.na. Metamizole is a white or almost white crystalline powder, very soluble in water and soluble in alcohol. it is a well established active substance and is the subject of a monograph in the european Pharmacopeia. Metamizole belongs to the following therapeutic groups: nSAiDs, nonnarcotic analgesics. Atc code is n02BB02.
and there is evidence that this drug is able to stimulate the release of pituitary and hypothalamic β-endorphins. In particular, metamizole increases the antinociceptive effects of morphine in monoarthritic rats (48) . in addition, metamizole administration before surgery has been reported to reduce the postoperative consumption of morphine in humans (98) . At present, the mechanism of action of the morphine-metamizole synergism is not clear, because the participation of central and peripheral pathways has not yet been systematically studied.
Antipyretic effect the neurochemical mechanism underlying the strong antipyretic effect of metamizole is not fully understood, but there is evidence that it acts centrally on the hypothalamic heat-regulating center to reduce fever, or the inhibition of prostaglandin synthesis (or a step before prostaglandin e 2 formation) in the central nervous system (cnS) could contribute to its antipyretic effect. however Malvar et al. (64) demonstrated that the antipyretic effect of metamizole was not mechanistically linked to the inhibition of hypothalamic prostaglandin e 2 synthesis. As for antinociceptive action, the antipyretic effect of metamizole could be due to still unidentified mechanisms.
Anti-inflammatory activity
Metamizole has weak anti-inflammatory activity. Tatsuo et al. (96) studied the analgesic and antiinflammatory effects of metamizole, indomethacin and dexamethasone in a model of chronic inflammation (adjuvant-induced arthritis in rats). Metamizole was shown to be more potent as an analgesic than as an anti-inflammatory agent, while indomethacin and dexamethasone also had a pronounced anti-inflammtory effect. these results indicate that metamizole reduces the hyperalgesia and edema in arthritic rats by a mechanism not involving release of prostaglandin-like substances. The antiinflammatory activity of metamizole is weaker, possibly because it has a low affinity for COX in environments that are high in peroxide, such as inflamed tissues.
effects on coagulation the effect of nSAiDs for reduced platelet aggregation and thromboxane A2 synthesis has been well documented. For metamizole, a dose-dependent effect on platelet aggregation through the inhibition of tXA 2 synthesis in platelets has been reported (28, 37, 87) . in a double-blind, randomized, parallel group trial Graff et al. (42) estimated the effect of metamizole on platelet aggregation in 26 patients scheduled to undergo routine partial meniscectomy. All patients received doseadjusted enoxaparin before surgery and parecoxib 40 mg BiD or metamizole 1 g qiD. Platelet aggregation and tXB 2 formation were significantly lower for 6 hours in metamizoletreated patients compared with those in parecoxib-treated patients. Most recently, Parkhutik et al. (77) has also reported anti-aggregating effects of metamizole in patients with subarachnoid hemorrhage (SAh).
other effects
Metamizole also possesses a distinctive spasmolytic effect on smooth muscles (44) . it has been shown that metamizole reduces the common bile duct and oddi sphincter tonus in a dose-dependent manner as well as the efferent urinary tract and urinary vesicle motility. in the last 10 years the interest in this compound has increased due to additional reported benefits, like antiapoptotic, neuroprotective, and anticonvulsant effects (68, 80, 82, 102) . there are animal studies which support the combined treatment with nSAiDs such as metamizole, with therapeutic hypothermia in order to render long-lasting neuroprotection. in animal models, metamizole delayed neuronal damage in the hippocampus, cortex, and striatum and prevented the complication of a secondary hyperthermic insult, as well as induced remarkable neuroprotection in cerebral ischemia (20, 113) . therapeutic hypothermia lowers the cerebral metabolic rate in anoxic brain injury and in cardiac arrest, has a protective effect during cardiac and intracranial surgical procedures, and has also been used in head-injured patients for the control of increased intracranial pressure (3).
safety Pharmacodynamics bone marrow suppression the safety of metamizole has been considered as questionable for many years due to the possible risk of agranulocytosis. Because of this, metamizole has been banned in the USA and many other countries, while it remains on the market in the rest of the world and in some counries, like Bulgaria, it is even otc.
Metamizole can induce agranulocytosis in certain patients (67) . the average risk of developing agranulocytosis after 1 week of treatment has been estimated to be 1.1 cases in 1 million consumers (51, 52) . the underlying mechanism may be cytotoxic lymphocytes which generate killer cells against drug-coupled bone marrow granulocytic cells. it has been suggested that some genetic mechanisms might be involved in metamizole-related agranulocytosis. While hlA-B24 and hlA-DqW1 were frequently positive, also some constitutional chromosomal changes and deletions chromosome 1 (1p13), chromosome 2 (2p12), chromosome 5 (5p12) were seen in these patients. in the assessment of a patient suffering metamizole-related agranulocytosis and thrombocytopenia not only myeloid precursors, but also multipotent (CFUmix) and erythroid (BFU-E) progenitors were shown to be inhibited (32) . the results from Garcia-Martinez et al. (36) study, show that metamizole and MAA neither affect the granulocyte differentiation process nor induce relevant apoptosis on terminally differentiated granulocytes. these results indirectly support that the mechanism of metamizoleinduced agranulocytosis should be of immunoallergic origin, since a toxic effect of this drug is excluded.
Another evaluation of epidemiological studies showed that the estimated excess mortality per million users due to community-acquired agranulocytosis, aplastic anemia, anaphylaxis, and serious upper gastrointestinal complications is 0.2 for paracetamol, 0.25 for metamizole, 1.85 for aspirin and 5.92 for diclofenac (4) . the authors concluded that the differences are due to gastrointestinal complications that represent the main cause of nSAiD-induced mortality. however, a persisting debate concerning metamizole's risk of agranulocytosis hampered further clinical investigations with the drug.
A French study on drug use and aplastic anemia has demonstrated no correlation between this condition and previous use of metamizole derivatives. the "international Agranulocytosis and Aplastic Anemia Study" showed up a slightly increased risk for agranulocytosis among metamizole users in some regions but not in others. however, it is important to point out that the absolute risks detected in that study were very low (51) . in thailand, a cooperative study between thai and American researchers brought out the same result, i.e. no material association between metamizole derivatives and aplastic anemia was detected. A case-controlled Brazilian study on the epidemiology of aplastic anemia and its risk factors, analyzed several associations between drugs and aplastic anemia, with a particular focus on metamizole. the results do not show any association between metamizole use and aplastic anemia (9) . effects on the gastro-intestinal system At the gastrointestinal level, PGs have a drastic protective role. Besides coX enzymatic participation, other mechanisms to explain nSAiD gastrointestinal damage have been proposed: vascular responses with no participation, neutrophil infiltration, cytokines production, or de-regulation of proliferation/apoptotic pathways. Sanchez et al. (86) comparing the gastric mucosal injury induced by the analgesic-antipyretic drugs, metamizole and paracetamol, both with relatively weak anti-inflammatory effects, with diclofenac, confirmed the favorable gastric tolerability of metamizole, similar to that of paracetamol.
effects on the respiratory system Metamizole may induce bronchospasm in aspirin-sensitive asthmatics (8) . however, in one-centered, non-randomized, non-comparative, open-labelled study involving 15 normal healthy volunteers and 15 coPD patients treated with metamizole at a dose of 20 mg/kg, all of the volunteers and coPD patients except one in the coPD group completed the study without any adverse events during the study. An adverse event, characterized by dyspnea, wheezing and cough occurred in one coPD patient 45 min after metamizole intake. the patient recovered totally after treatment with bronchodilators. the patient was excluded from the study. the relation between drug exposure and the bronchospasm was estimated as ''possible''. the authors conclude that metamizole can be safely used in such patients when indicated (44) . An improved small airway function in asthmatic patients with moderate airway obstruction was also observed in an open-label study involving 22 asthma patients (45) .
Persistence of Efficacy and/or Tolerance Effects
in animal studies, tolerance to repeated metamizole administration was observed. the mechanism of action underlying this process is still unclear but it appears to be partially related to the release of endogenous opioids (47, 106) . Vasquez-Rodriguez et al. (107) showed that microinjection of metamizole into the PAG causes naloxone-reversible antinociception and induces tolerance with cross tolerance to morphine, and interestingly, crosstolerance to metamizole. Silva-Moreno et al. (91) (26) studied the possible development of tolerance produced by the combination metamizole and morphine (562.3 mg/kg and 5.6 mg/kg, respectively) during subchronic treatment (6 and 12 days) in arthritic rats. the development of tolerance to the analgesic effect was observed after 6 days and 12 days of morphine administration. however, the analgesic effect produced by the metamizole and morphine combination remained constant (near 100 %) during both subchronic treatments. these data demonstrate that metamizole significantly attenuates the development of tolerance to morphine. the mechanism involved in this effect of metamizole remains to be unclear. These findings also suggest that both opioids and nonopioids may share mechanisms of action when systemically administered at therapeutic doses.
Pharmacokinetics Absorption
Metamizole is rapidly and almost completely absorbed after oral administration approching 100 % bioavailability (30, 97) . it is non-enzymatically hydrolyzed in the gastrointestinal tract to 4-methylaminoantipyrine (MAA), which is rapidly and nearly completely absorbed, reaching peak levels within 1 or 2 h (34, 108, 109) . the parent compound metamizole is not detectable in the plasma, but at least seven metabolites occur instead. the rate of absorption is similar in young and elderly patients. The effect of food is clinically insignificant (34, 116) . distribution the volume of distribution (Vd) values for metamizole and MAA are 0.7 l/kg and 0.61 l/kg, respectively. the presence of metabolites MAA, 4-aminoantipyrine (AA), 4-formylaminoantipyrin (FAA) and 4-acetylamino antipyrine (AAA) has been detected in cerebrospinal fluid (CSF) due to their lipid solubility (19) . The CSF/plasma ratio was higher for the metabolites MAA and AA, which have a higher lipophilicity. in contrast, saliva plasma ratios were low for these metabolites and relatively high for the metabolites with low protein binding such as FAA and AAA. The extent of plasma protein binding is 57.6 %, 47.9 %, 17.8 % and 14.2 % for MAA, AA, FAA and AAA, respectively (114) .
Metabolism
Metamizole is a prodrug which is extensively metabolized initially by hydrolysis in the gastrointestinal tract to the active metabolite, MAA (31, 34, 108, 109) . in the liver MAA is metabolized to a second active metabolite, AA. AA is acetylated to AAA by a polymorphic n-acetyltransferase (nAt2) system (37) . cytochrome P-450 oxygenases are involved in the metabolism of MAA to FAA ( fig. 1) . the enzyme likely to be responsible for MAA metabolism, is cytochrome P450 3A4 (19) . the metabolism of metamizole is not influenced by the acetylation phenotype (5, 56) .
the analgesic effect of metamizole correlates with the concentration of MAA and AA, which differ with regard to their time of onset (MAA > AA) and terminal half-life (MAA: 2.2-3-7 h, AA: 5-8 h). MAA is around 50 times more active than metamizole as an inhibitor of coX, while AA is less active than metamizole. therefore both metabolites contribute to the clinically relevant features of rapid onset and long duration of the effect, permitting 6-8 hourly dosing intervals. The halflife of MAA, however, is dose-dependent (63) . the other 2 metabolites, FAA and AAA, are inactive. The metabolites, which generate the excellent analgesic action as well as the severe side effects, are still unknown.
Most recently, Rogosch et al. (84) reported two unknown metabolites of metamizole, arachidonoyl amides of MAA and AA, identified by ESI-LC-MS/MS after extraction from the cnS. the arachidonoyl amides arachidonoyl-4-methylaminoantipyrin and arachidonoyl-4-aminoantipyrin bound to both human recombinant cannabinoid cB1 and cB2 receptors at micromolar concentrations, and arachidonoyl-4-methylaminoantipyrin concentration-dependently inhibited coX isoforms, PGe2 and PGi2, and lPS-induced PGe2 formation in mouse brain homogenates at nano-or micromolar concentrations that are attainable at therapeutic dosage of metamizole (500 mg to 1000 mg). eliminatin half-life the elimination half-life of both active metabolites (MAA and AA) is at a slow degree dose dependent. in healthy humans it ranges for MAA between 2.5 h (750 mg metamizole) and 3.5 h (3000 mg metamizole); and for AA, between 4 h and 5.5 h, respectively. the elimination of MAA is prolonged in elder (t 1/2 = 4.5 h) compared to young subjects (t 1/2 = 2.5 h). the prolongation correlates with the creatinine clearance (108, 109) .
other pharmacokinetic data hepatic impairment: in patients with chronic liver disease, the disposition of metamizole metabolites is reduced. Asymptomatic carriers of the hepatitis B virus with normal liver function tests demonstrated impaired oxidative metabolism of metamizole when compared with healthy subjects (58) . in hepatic impaired patients, the elimination of MAA is rather delayed in comparison to healthy volunteers. in cirrhotic patients the mean plasma half-life of MAA is increased approximately 4-fold in comparison to that in healthy people (115) . renal impairment: no alteration in metamizole elimination was found in patients with chronic renal impairment. however, critically ill patients with acute renal failure have demonstrated a prolonged half-life for MAA, ranging from 2.5 h to over 40 h, which may have contributed to serious reactions due to drug accumulation. Alteration in dosing may be necessary in patients with acute renal failure or impaired cardiovascular function due to shock. elderly people: in a population pharmacokinetic analysis of MAA, including 153 patients, levy et al. (57) concluded that the age is a significant predictor of MAA disposition. the results of the analysis show considerable variability in pharmacokinetics across the study population, and a significant decrease in clearance with age.
Analytical Methods for determination of Metamizole
Pharmacopoeian method iodometric titration with 0.05 mol/l iodine after dissolution in 0.01 mol/l hydrochloric acid.
other Methods there are a huge number of described methods for the determination of metamizole sodium. liu and huang (59) proposed a simple, sensitive and reproducible method for the determination of metamizole in ethanol by a charge transfer Spectral Method with satisfactory results. Shi and Song (88) described a spectrophotometric method for the quantitative determination of dipyrone tablets. Ma (62) developed an ironic rhodanate fading spectrophotometric method for the determination of metamizole in preparations. Zhang and Song (112) observed that metamizole could sensitively inhibit the chemiluminescence (cl) reaction of luminol and K 3 Fe(CN) 6 . the decrement of cl intensity was proportional to the concentration of metamizole. this system has been applied for the determination of metamizole in pharmaceutical samples, serum and human urine. Another cl method based on the chemiluminescent reaction between quinolinic hydrazide and hydrogen peroxide in a strongly alkaline medium, in which vanadium(iV) acts as a catalyst, was proposed by Pradna Perez et al. (81) . Pauliukaite et al. (78) developed a rapid electrochemical procedure for the determination of metamizole at a carbon nanotube modified graphite-epoxy resin electrode.
determination of metamizole metabolites in biological samples
Some analytical methods are proposed for the determination of metamizole metabolites for the purpose of pharmacokinetic and biopharmaceutical investigations. Sistovaris et al. (92) developed thin-layer chromatographic (tlc) methods for pharmacokinetic studies of the major metamizole metabolites in serum and urine. however, the most applied technique for determination of metamizole metabolites is hPlc. Damm Zanger et al. (111) reported that human cYP2B6 is strongly inducible by numerous drugs and chemicals, including metamizole. Drugs known to be substrates of cYP2B6 are bupropion, cyclophosphamide, efavirenz, ketamine, meperidine, propofol, selegiline, S-mephenytoin. Whether metamizole interacts with these drugs remains to be elucidated.
herb-drug interactions
We could not find any published information concerning metamizole-herb interactions, however the concomitant use of both herbal medicines and metamizole requires careful consideration. there are some reports of herb-induced aplastic anemia and agranulocytosis, mainly for traditional chinese medicines. there is also concern about the use of adulterated herbal medicines as the case of four non-chinese patients who developed agranulocytosis while taking chinese herbal medicine (widely available in the USA in the 1970s) for the relief of arthritis and back pain (83) . the herbal medicine was shown to contain substantial amounts of undeclared aminopyrine and phenylbutazone, the drugs well known to induce agranulocytosis. Some cases of herb-induced aplastic anemia have been reported (72, 93) . Gross et al. (43) reported that medicinal herb use was marginally, though not significantly associated with elevated risk for development of aplastic anemia. in recent years there has been an exponential increase in the use of medicinal herbal products around the world. An eventual concomitant administration of metamizole with potentially hematotoxic herbs or herbal medicines adulterated with undisclosed medicines could exponentially increase the risk of adverse reactions (24, 94) .
Potentiation of analgesic effect
Metamizole potentiates the analgesic and antipyretic action of other nSAiDs. Analgesic drug combinations are widely used in pain management in humans in order to enhance or preserve antinociception, and decrease side effects. the mechanisms responsible for the synergism in the analgesic activity of nSAiDs combinations are not clear; however, according to the published information, different systems are partially involved (70, 71) . the metamizole effects are potentiated by tricyclic antidepressants, oral contraceptive agents, allopurinol, B vitamins, and also alcohol (76, 99) .
opioid-sparing effect the combined administration of low doses of opiates with nSAiDs can produce additive analgesic effects. Analgesic potentiation has been reported for the combined administration of morphine and metamizole in different models of antinociception, including arthritic inflammation (48) , the formalin test (1); the tail flick test (14, 49) , and the writhing reflex test (97) . The synergy between opioids and nSAiDs could be related to endogenous opioid release and different pathways of pain transmission, probably related to the different intracellular signal transduction mechanisms of action of opioid and non-opioid agents (69) .
toxicology single-dose toxicity
Metamizole is of fairly low acute toxicity (lD50) by the oral and parenteral routes in rats, mice, guinea pigs and rabbits. in rat, the four major metabolites of metamizole MAA, FAA, AA and AAA had similar acute toxicity to the parent compound. central nervous system effects such as sedation and convulsions were reported in all species at dosages from 1000 mg/kg to 4000 mg/kg bw. in mice, the effects on the cnS were observed at oral doses in the range of 100 mg/ kg to 2000 mg/kg bw. in acute studies, metamizole showed no potential for gastric ulceration. No significant effects were observed on cardiovascular or respiratory parameters in anaesthetised cats and dogs (30 mg/kg to 300 mg/kg bw IV) (29, 30, 85) . Mao et al. (65) did not find any toxicity of intranasally administered metamizole at a dose of 1000 mg/kg.
repeat-dose toxicity
Repeated dose toxicity studies were performed in rats and dogs after per oral, intravenous and subcutaneous dosing. in all tested species reduced bodyweight gain and food consumption, increases in reticulocytes and heinz bodies, increases in liver, kidney and spleen weights were reported. local injection site reactions were also observed and were dose-related in severity. in dogs receiving 300 mg/kg and over, the histopathological effect was increased incidence of slight haemosiderosis of the liver (30, 54) .
Genotoxicity
Several in vitro assays for gene mutation were carried out using Salmonella typhimurium strains tA98, tA100, tA1535, tA1537 and tA1538, and Escherichia coli WP2uvrA. All the studies which were adequately described gave negative results. Positive results were claimed in published in vitro cytogenetic assays in human lymphocytes and in sister chromatid exchange (Sce) assays in chinese hamster cells but little or no information was provided concerning the test methods or the purity of the substances tested and full details of the results were not provided; the results were therefore difficult to interpret (39) . oral doses of 0 mg/kg, 25 mg/kg, 200 mg/ kg or 1600 mg/kg bw were administered to nMRi mice in an in vivo micronucleus test; a negative result was obtained but there was no positive control group and no evidence of bone marrow toxicity. A second in vivo micronucleus test was reported in the literature but gave no details beyond a statement that metamizole was positive. Published studies were also reported on the mutagenic potential of nitrosation products of metamizole in the in vitro assay for gene mutation in bacteria (Ames test); two studies claimed positive results, but the third, which was the most adequately reported, claimed negative results (16, 40, 55) . in well-conducted mutagenicity assays (in vitro gene mutations and in vivo micronucleus test), which were carried out in compliance with the Good laboratory Practice and relevant oecD guidelines, it was concluded that metamizole was not genotoxic (30) . carcinogenicity three carcinogenicity studies were carried out in mice. in two of them an increased incidence of liver tumors was found, while in the third (nMRi mice) liver weights were increased without corresponding histopathological changes. it was concluded that the liver tumours found in some strains of mice (B6C3F1, Balb/c and icR) were probably due to a non-genotoxic mechanism involving hepatotoxicity (16, 27, 29, 101) . it should be considered that genotoxic-carcinogenic effects may be produced in humans by the n-nitroso compounds formed in the gastric environment by the reaction with nitrite of nSAiDs which are theoretically nitrosatable amine drugs. Formation of n-nitroso compounds (noc) by reaction with nitrite has been found to occur for diclofenac, metamizole, indomethacin, and paracetamol (10) . no association between bladder cancer risk and metamizole regular use was found among slow, intermediate and rapid acetylators (35) .
Reproductive and developmental toxicity
The pregnancy category of metamizole is C (first and second trimester) and D (third trimester). even though to-date no fetotoxic effects have been observed, the use of metamizole is not recommended during pregnancy (6) .
the effects of metamizole on hyaluronidase activity of semen and sperm characteristics in rams were investigated by tanyildizi and Bozkurt (95) . Metamizole caused an increase in the hyaluronidase activities and spermatozoa motilities, and significantly decreased the sperm concentrations and semen volumes.
in a reproductive toxicity study, Sprague-Dawley rats treated with metamizole starting 2 weeks prior to mating and throughout pregnancy and lactation, the highest dose (625 mg/kg bw/day) was toxic to the dams and caused 6 deaths associated with gastric haemorrhage, reduced body weight gain and food consumption and enlarged spleens. there were significant reductions in the numbers of pups born per dam. Pup survival was also reduced at 250 mg/kg bw/day. After weaning, selected males and females from the F1 generation were mated; these rats remained untreated throughout mating and gestation; no significant effects were observed. The NOEL was 100 mg/kg bw/day. no adverse effects on litter or foetal parameters were reported in dams sacrificed on day 20 after treatment with metamizole (30) .
Pregnant rats treated with metamizole during the embryogenic (from the 5 th to the 15 th day of pregnancy) and fetal (from the 15 th day of pregnancy until term) periods showed reduction in the number of liveborns due to an increase in reabsorptions and stillborns, respectively. the morphological and biochemical action of metamizole on the placenta of albino rats studied by esperidiao et al. (33) , showed that the effects of metamizole are more intense in the beginning of pregnancy (9 th to 12 th day of pregnancy), mainly during the phase of formation and placental differentiation. in teratology studies with Sprague-Dawley rats, Wistar rats and new Zealand White rabbits, metamizole induced an increased incidence of resorptions with corresponding reductions in the total number of fetuses and the numbers of foetuses per dam, without evidence of teratogenicity, with no malformation found in any group (29) .
other toxicity studies there are two major types of adverse reactions to pyrazolones, allergy and intolerance. A relatively high incidence of allergic reactions to metamizole has been described in humans. the presence of an ige-mediated allergy to such drugs can be confirmed by skin prick tests and intradermal testing. Patients with intolerance to metamizole usually have asthma, chronic rhinitis, nasal polyps, and sensitivity to other coX inhibitors. the probable pathogenesis is non-immunologic or pseudoallergic (8) . Metamizole may cause haemolytic anaemia in patients with a deficiency of glucose-6-phosphate dehydrogenase, due to inhibitiory effect on the activity of the enzyme (18) . conclusions this review provides the up-to-date integrated and critical overall analysis of scientific pharmaco-toxicological information concerning metamizole, a pyrazolone nonsteroidal anti-inflammatory agent. Similar to other NSAIDs, metamizole exhibits analgesic, and antipyretic activity, determined by the central and peripheral mechanism of action. Metamizole is rapidly and almost completely absorbed after oral or parenteral administration. however it is not absorbed intact and its activity is very largely due to its immediate metabolite, MAA. the majority of the administered dose (more than 90 %) is excreted in the urine as metabolites. Metamizole is of fairly low acute toxicity. in chronic toxicity studies data indicate that the incidence of adverse reactions in the target species is very low. Metamizole gave both positive and negative results in either genotoxicity or carcinogenicity assays. All the studies which were adequately described gave negative results. there is some evidence that metamizole might induce liver tumors in some strains of mice, probably due to a non-genotoxic mechanism involving hepatotoxicity. there is no evidence of embryotoxic or teratogenic potential of metamizole. in summary, as there is now almost 90 years of experience with the use of metamizole in humans and a lot of safety data are available, the analysis of the preclinical pharmacological and toxicological data available in the literature shows that metamizole has a good preclinical safety profile.
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